"In normal times, rare diseases don’t always receive a high level of attention from the medical community. But, during the COVID-19 pandemic, it can seem that rare disease is even further down the agenda", says Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
"An incredible amount of attention has understandably been dedicated to COVID-19. This has had an impact on those living with other health conditions, including rare diseases. Throughout the crisis, pharma companies have worked tirelessly to ensure the continuity of clinical trials in extremely challenging circumstances."
Join our next debate about the root causes of unavailability of medicines and delays for patients across the EU
#QuestionsInspireSolutions...
Read more
#WeWontRest until Alzheimer's patients see a brighter future
Out of 300 candidates, nine are in phase 3 trials, with some hoping for emergency use approval this year
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.